Growth Factors, Cytokines, Cell Cycle Molecules

Sera from Preeclampsia Patients Elicit Symptoms of Human Disease in Mice and Provide a Basis for an in Vitro Predictive Assay

Satyan Kalkunte,* Roland Boij,† Wendy Norris,* Jennifer Friedman,‡ Zhongbin Lai,* Jonathan Kurtis,‡ Kee-Hak Lim,§ James F. Padbury,* Leif Matthiesen,¶ and Surendra Sharma*

From the Department of Pediatrics,* Women and Infants Hospital–Warren Alpert Medical School, and the Lifespan Center for International Health Research,† Brown University, Providence, Rhode Island; the Faculty of Health Sciences,‡ Linkoping University Medical School, Linkoping, Sweden; the Department of Obstetrics and Gynecology,§ Harvard Medical School, Boston, Massachusetts; and the Department of Obstetrics and Gynecology,¶ Helsingborg Hospital, Helsingborg, Sweden

Early diagnosis and treatment of preeclampsia would significantly reduce maternal and fetal morbidity and mortality. However, its etiology and prediction have remained elusive. Based on the hypothesis that sera from patients with preeclampsia could function as a “blueprint” of causative factors, we describe a serum-based pregnancy-specific mouse model that closely mirrors the human condition as well as an in vitro predictive assay. We show that a single administration of human preeclampsia serum in pregnant IL-10−/− mice induced the full spectrum of preeclampsia-like symptoms, caused hypoxic injury in uteroplacental tissues, and elevated soluble fms-like tyrosine kinase 1 and soluble endoglin, markers thought to be related to the disease. The same serum sample(s) induced a partial preeclampsia phenotype in wild-type mice. Importantly, preeclampsia serum disrupted cross talk between trophoblasts and endothelial cells in an in vitro model of endovascular activity. Disruption of endovascular activity could be documented in serum samples as early as 12 to 14 weeks of gestation from patients who subsequently developed preeclampsia. These results indicate that preeclampsia patient sera can be used to understand the pregnancy-specific disease pathology in mice and can predict the disorder. (Am J Pathol 2010, 177:2387–2398; DOI: 10.2353/ajpath.2010.100475)

Preeclampsia is a systemic syndrome that occurs in about 5% to 8% of pregnancies worldwide.1 This disorder is diagnosed in the second half of pregnancy and represents a leading cause of maternal and fetal mortality and morbidity. Since the preeclampsia-associated clinical features resolve after delivery, dysregulated placental development and function have long been thought to contribute to the pathogenesis of this pregnancy complication.2 It is surprising that, despite the abundant clinical knowledge of this syndrome, no definite etiology or predictive diagnostic tests have been identified. This situation is exacerbated by the likely multifactorial etiologies that contribute to the symptom complex we label as preeclampsia. Heterogeneity of the disorder is further exemplified by the range of clinical manifestations that present with or without fetal growth restriction, mild or severe pathology, resulting in induced preterm or term delivery, and the influence of a wide range of maternal factors.3,4 At the maternal-fetal interface, superficial placentation coupled with immune maladaptation, imbalance in angiogenic growth factors, and increased placental debris in the maternal circulation has been suggested to contribute to the disease.5–9 Because of the placental deficiencies and ensuing maternal syndrome, preeclampsia is considered to be a culmination of at least two stages of disorder. The first stage is characterized by placental ischemia leading to release of soluble factors from placenta, which is thought to initiate the second stage of maternal response.10,11 In this context, in...
creased circulating levels of anti-angiogenic factors, soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sEng), have been proposed as the soluble components possibly initiating the maternal symptoms. These factors are reported to be altered several weeks preceding clinical disease. However, the etiologic heterogeneity is reflected by the fact that preeclampsia also occurs in some women with low circulating sFlt-1 and sEng levels and high placenta growth factor (PiGF). Recent studies have also described high circulating levels of autoantibodies against angiotensin receptor-1 (AT1-AAs) in women with preeclampsia. Surprisingly, when the anti-angiogenic factors and AT1-AAs were tested in rodent models, they resulted in only partial manifestation of the human condition. This suggests regulatory contributions by additional environmental, genetic, and/or nutritional factors in the onset of the syndrome. A less appreciated aspect of these elegant studies is the same experimental paradigm leads to induction of hypertension and proteinuria in nonpregnant animals. Whether this is a pointing by upstream regulatory factors that trigger the placental pathology or reflects a different pathophysiologic response than “true” preeclampsia is not known. Moreover, AT1 receptor antagonist therapy or hypertension controlling drugs such as angiotensin converting enzyme (ACE) inhibitors are not the choice of treatment for preeclampsia.

The relatively late onset of clinical presentation and lack of well defined in vitro and in vivo models have further hindered our understanding of the causative factors of the preeclampsia syndrome and the development of therapeutic interventions. Several reports have described mouse models that mimic only partial features of the human condition or have been questioned for similar features in nonpregnant mice or lack of features under environmentally challenged conditions. Thus, there is an urgent need for a well defined pregnancy-specific experimental model that can closely mirror the human condition and encompasses the contribution of predisposing factors. We and others have demonstrated in both human and mouse models that interleukin (IL)-10 is a critical cytokine for normal pregnancy outcome, particularly in response to inflammatory triggers. Importantly, pregnant IL-10−/− animals were found to be highly sensitive to low doses of inflammatory triggers leading to fetal demise, premature delivery, and intrauterine growth restriction (IUGR), features common to preeclampsia. This suggests that IL-10−/− mice may provide a model system for studying pregnancy complications including preeclampsia. Indeed, reduced IL-10 has been described in placental tissue from preeclampsia deliveries.

The endovascular transformation of spiral arteries, under the influence of the triomvirate of endothelial cells, trophoblasts, and uterine natural killer cells, is essential to the maintenance of placental perfusion. Although elegant arguments have been made for disordered velocity of blood flow in causing placental pathology, dysregulated endovascular cross talk between trophoblasts and endothelial cells in spiral artery remodeling remains an important but understudied pathway. We pos-

Materials and Methods

Patients and Serum Collection

Preeclampsia was defined by systolic blood pressure of more than 140 mmHg and diastolic blood pressure of more than 90 mmHg after 20 weeks’ gestation in a previously normotensive patient and new onset proteinuria (>300 mg of protein in a 24-hour urine collection or a random urine protein/creatinine ratio of >0.3). Patients with baseline hypertension, proteinuria, renal disease, diabetes, and twin pregnancy were excluded. For the purposes of this study, patients were divided into groups with mild and severe preeclampsia on the basis of the recently published American College of Obstetricians and Gynecologists criteria. Healthy, normotensive pregnant women (the “normal” group) were included as controls. Blood was obtained from normally cycling women and pregnant women during 12 to 14, 24 to 27, and 32 to 36 weeks of pregnancy with informed consent, under the approved protocols by the institutional review boards of participating institutes, Women and Infants Hospital of Rhode Island, Beth Israel Deaconess Medical Center, Lifespan-Rhode Island Hospital, and Linkoping University Hospital (Linkoping, Sweden). Serum was separated and frozen as aliquots at −80°C until further use. The clinical characteristics of subjects are provided in Supplemental Table 1 at http://ajp.amjpathol.org.
Animal Studies

All animal protocols were approved by the Lifespan Institutional Animal Care and Use Committee. C57BL/6 wild type or IL-10−/− mice were housed and mated in a specific pathogen-free facility under the care of the Central Research Department of Rhode Island Hospital. All mating experiments were repeated at least three times with at least four to six mice per treatment. The day of vaginal plug appearance was designated gestational day (gd) 0. We administered i.p injection of severe (n = 8) or mild (n = 5) preeclampsia serum (100 µl) per mouse or an equivalent volume (100 µl) of normal pregnancy serum (n = 9) as control to pregnant C57BL/6 wild type or IL-10−/− mice on gd 10. On gd 17, after the blood pressure recoding, the animals were euthanized, the uteroplacental units were photographed, and fetal weights were recoded. Similarly nonpregnant female mice were injected for comparative analysis after 7 days. For monitoring the influence of AT1-AAs in the serum samples, pregnant mice were co-injected with normal pregnancy serum or severe preeclampsia serum and were processed on gd 17 as described.

Assessment of Proteinuria

On gd 16, the animals were transferred to individual metabolic cages. Samples of urine were collected over 24 hours, aliquot, and stored at −80°C until further analysis. Total urinary albumin was measured by using Albumin (mouse) enzyme-linked immunosorbent assay (ELISA) kit (ALPCO Diagnostics, Salem, NH), which is based on double antibody sandwich ELISA according to the manufacturer’s protocol. The kit is highly sensitive and can detect albumin levels at 1:10,000 dilutions. To normalize the albumin, urinary creatinine was measured by using Metra Creatinine Kit (Quidel Corporation, San Diego, CA), which is based on modified Jaffe method according to the manufacturer’s protocol. Proteinuria was represented as the ratio of urinary albumin to creatinine and was expressed as microgram per milligram.

Measurement of Blood Pressure

Blood pressure was recorded by an established tail-cuff method that utilizes a programmed sphygmomanometer. The animals were adapted for 5 minutes in a warming test chamber (IITC Life Science Inc, Woodland Hills, CA) at a controlled temperature (35°C). These measurements were carried out on gd 17 of pregnancy by using DigiMed blood pressure analyzer (MicroMed, Louisville, KY). Each measurement of blood pressure was an average of three readings at a 1-minute interval from a number of animals (~ five to six each). Systolic blood pressure was compared with pregnant mice with and without treatments. Nonpregnant animals were also treated with normal pregnancy serum or preeclampsia serum and after 7 days, blood pressure was similarly recorded. Data were analyzed by using Digi-Med System Integrator Model 400 (DMSI-400; MicroMed, Louisville, KY).

Assessment of Renal Pathology

Kidney tissue were harvested from gd 17 mice, fixed in 10% buffered formalin, and were stained with hematoxylin/eosin and periodic acid Schiff for histopathological examination. A number of randomly selected glomeruli were assessed by at least two pathologists. Morphological changes were recorded by using SPOT Advanced software (Diagnostic Instruments, Inc, Sterling Heights, MI) at ×100 magnification (Nikon Eclipse 80i microscope; Avon, MA).

Evaluation of Spiral Arteries

Placental morphology and spiral arteries were monitored by harvesting uteroplacental units on gd 13, fixed and paraffin embedded, and sectioned and stained with H&E staining as described. We then acquired the images with a Nikon Eclipse 80i microscope (Nikon) at ×4 magnification. Morphometric analysis of spiral arteries was carried out by using the SPOT Advanced software (Diagnostic Instruments, Inc) at ×40 magnification (Nikon Eclipse 80i microscope). Average area of spiral arteries (at least six per implantation site) were calculated from three independent animals per group as reported elsewhere.

Assessment of Hypoxia

In vivo hypoxia was detected by using the marker EF5, a gift from Dr. Cameron Koch. EF5 (2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide) is reduced under hypoxic conditions and the reduced form reacts with cellular macromolecules, thereby demarcating regions of hypoxia. Briefly, EF5 (10 µmol/L) was administered i.p. 4 hours before harvesting the uteroplacental units on gd 14. The units were snap-frozen and 10-µm sections were processed and probed for bound EF5 by using ELK3-51 antibody (1:30) as described.

Western Blotting

To further confirm that treatment with preeclampsia serum did indeed induce hypoxia, placental units were harvested between gd 12 and 14 and were lysed with cell lysis buffer (Cell Signaling, Danvers, MA). The proteins from tissue lysates were separated on 12% SDS-polyacrylamide gels and blotted onto polyvinylidene difluoride membranes and probed with antibodies for hypoxia-inducible factor (HIF 1α) (Santa Cruz Biotechnology, Santa Cruz, CA) and β-actin (BD Biosciences, San Jose, CA). Enhanced Chemiluminescence (ECL) (Amersham Biosciences, Piscataway, NJ) was used to visualize the
bands, and we recorded them by using Konica SRX 101A developer.

**Enzyme-Linked Immunosorbent Assay**

To assess the biochemical changes associated with preeclampsia, blood from gd 17 mice were collected by cardiac puncture. Serum was separated from cellular mass by brief centrifugation and stored at −80°C until further use. The serum levels of sFlt-1 and sEng (R&D Systems, Minneapolis, MN) were measured according to the manufacturer’s instructions in duplicates.

**Trophoblast Cells and Endothelial Cells**

Immortalized first trimester trophoblast cell line HTR8 with properties of extravillous cytotrophoblasts was established and kindly provided by Dr. Charles Graham. HTR8 cells were grown to ~80% confluence in RPMI standard growth medium and used only during eight passages. Human umbilical cord endothelial cells were obtained from Cambrex (East Rutherford, NJ) and cultured in complete endothelial basal media (EBM-2, Cambrex). All cells were maintained in standard culture conditions of 5% CO₂ at 37°C.

**In Vitro Three-Dimensional Tube Formation Assay**

We have recently established a serum based three-dimensional dual cell culture model to study endovascular activity involving trophoblasts and endothelial cells. This model was used to evaluate the differential effects of pregnancy serum. Briefly, trophoblasts or endothelial cells (2.5 × 10⁴), labeled with cell tracker green CMFDA or cell tracker red CMTMR (Molecular Probes, Eugene, OR), respectively, were co-cultured on matrigel coated plates in the presence of serum from normal pregnancy or preeclampsia. Serum-initiated endothelial cell-directed tube formation by trophoblasts was monitored and recorded as described earlier. For evaluating the sensitivity of the model to distinguish samples, nonpregnant female serum, normal pregnancy serum, or preeclampsia serum at term were tested at different concentrations (1%, 2.5%, 5%, and 10% v/v) in serum free media. Interestingly, in our studies lower concentrations of preeclampsia serum (1% and 2.5% v/v) did not disrupt the endovascular interactions, whereas at 5% and 10% v/v the tube disruption was predominant, suggesting a dose-response relationship. Based on the initial dose-related findings, we routinely used 10% v/v of normal pregnancy serum or preeclampsia serum for majority of studies unless specified. To evaluate the system to predict the onset of preeclampsia, serum samples from 12 to 14 (n = 18), 24 to 27 (n = 5), and 32 to 36 (n = 22) weeks of gestation were tested and compared with gestational age-matched normal pregnancy serum. The average number of tubes/vacuoles formed was quantified as described earlier.

**Cytotoxicity Assay**

Endovascular disrupting activity could be either due to cytotoxicity imparted by the serum samples or due to factors that perturb the molecular signaling in the endothelial or trophoblast cells. Thus, we evaluated the cytotoxic potential of pregnancy serum on endothelial cells and trophoblasts by propidium iodide staining. Briefly, 0.25 × 10⁶ endothelial cells or trophoblasts were cultured overnight in a 12-well culture plate in complete EBM-2 or RPMI media. The cells were then incubated with serum free RPMI media containing 10% v/v of normal pregnancy serum or preeclampsia serum for another 24 hours, harvested by cell scraping, and washed with PBS. The cells were stained with propidium iodide (1 µg/µl) by incubating at 37°C for 1 hour, washed, and resuspended in Fluorescence-Activated Cell Sorting (FACS) buffer. The stained cells were then acquired (10,000 cells) and analyzed by FACS Calibur (Becton Dickinson, Franklin Lakes, NJ).

**Statistics**

Statistical analyses were performed by using Microsoft Excel software version 11.1.1 and Jump version 8.0.2. Normality diagnostics were first performed for all analyses to guide choice of parametric or nonparametric tests. For normally distributed data, two-tailed Student’s t-tests were used. P values less than 0.05 were considered significant. For data with poor normal distribution, the Kruskal-Wallis test was used.

**Results**

**In Vivo Effects of Human Preeclampsia Serum on Fetal Weight, Blood Pressure, and Proteinuria**

Recent reports suggest that adenoviral delivery of sFlt-1 and sEng in pregnant mice induce preeclampsia-like symptoms. However, this vector system induces much higher levels of these anti-angiogenic factors in animals when compared with levels present in serum collected from patients with preeclampsia. We screened by ELISA a series of serum samples from normal pregnancy subjects and patients with preeclampsia given a diagnosis of either mild or severe conditions. Our data on sFlt-1 and sEng show higher average values in patients with preeclampsia compared with normal pregnancy samples (Kruskal-Wallis P < 0.0001 and P < 0.0005, respectively; see Supplemental Figure S1 at http://ajp.amjpathol.org), in agreement with the published reports. However, we did not observe a cross-sectional relationship with the incidence of preeclampsia, as several serum samples from this group had comparable values with normal pregnancy samples (see Supplemental Figure S1 at http://ajp.amjpathol.org). This suggests that other factors must contribute to induction of this disorder in humans. To address our hypothesis that serum could blueprint the symptoms of preeclampsia, we injected i.p. a volume of 100 µl of individual serum samples from normal pregnancy (n = 9) or from severe (n = 8) or mild (n = 5)
Preeclampsia including those with low sFlt-1 and sEng values. Serum was injected into pregnant wild type and IL-10−/− mice on different gds (see Materials and Methods). Our pilot experiments suggested gd 10 as the most suitable time for serum administration as injection of severe preeclampsia serum on gd 8 resulted in significant intrauterine fetal death as confirmed by evaluation of uterine horns on gd 17 (see Supplemental Figure S2 at http://ajp.amjpathol.org). Similarly, injection on gds 13 to 14 did not cause any significant pathology. Accordingly, we used gd 10 for subsequent studies of the effects of preeclampsia serum administration. Injection of severe preeclampsia serum resulted in elevated blood pressure (Figure 1A) and proteinuria (Figure 1B) in IL-10−/− mice as well as wild type counterparts. However, as seen in the Figure 1, A and B, elevated blood pressure and proteinuria were observed only in IL-10−/− mice in response to mild preeclampsia serum samples, suggesting that IL-10 deficient mice are more susceptible to developing preeclampsia when challenged with serum from patients with this syndrome. Treatment of pregnant IL-10−/− mice with serum from severe preeclampsia invariably resulted in IUGR (Figure 1C), a phenomenon not observed with samples from mild preeclampsia. Surprisingly, fetal weights were not significantly affected in wild type mice by even severe preeclampsia samples (Figure 1D). The effects of preeclampsia serum cannot be directly attributed to human sFlt-1 and sEng because their absolute values in 100 μl samples are relatively low (~5 ng and ~15 ng, respectively). Similarly, our observations could not be attributed to the presence of AT1-AAs in preeclampsia serum because co-treatment with AT1 receptor antagonist losartan or neutralizing AT1 receptor epitope binding 7-amino acid peptide in IL-10−/− mice did not reverse the abnormalities in fetal weight, blood pressure, and proteinuria (see Supplemental Figure S3, A–D, at http://ajp.amjpathol.org).

Renal Pathology Is Associated with Treatment with Preeclampsia Serum

Glomerular endotheliosis and impaired renal function are cardinal features of preeclampsia.52 To assess whether preeclampsia serum samples cause renal pathology, kidney tissue was harvested from the different treatment groups and stained as described in Materials and Methods. Figure 2A depicts the renal lesions that were observed after administration of severe preeclampsia serum and normal pregnancy serum in pregnant mice. Typical glomerular endotheliosis, characterized by obliteration of Bowman’s capsule and increased infiltration of protein droplets in the
Intraluminal spaces and hypertrophy of endocapillary cells was observed in both IL-10
/H11002
/H11002
mice and wild type animals in response to preeclampsia serum. Similar changes were observed in pregnant mice treated with high doses of sFlt-1 and/or sEng (data not shown), in agreement with the reported observations in rats.49,51 Pregnant mice treated with normal pregnancy serum did not show any signs of kidney pathology (Figure 2A). Treatment with mild preeclampsia serum did not result in severe kidney pathology (data not shown), a possible explanation for the only moderate proteinuria readings observed (Figure 1B). The glomerular endotheliosis noted after administration of severe preeclampsia serum was consistent in all experiments and parallels the observations seen in renal biopsies in human preeclampsia.52

Administration of Preeclampsia Serum Induces Excess Production of Mouse sFlt-1 and sEng

Excess presence of sFlt-1 in circulation, possibly released by the placenta, has been detected in a significant proportion of patients with preeclampsia. It has been thought to be associated with endothelial dysfunction, hypertension, and proteinuria.6,13,14,49 Moreover, sEng has been shown to act synergistically with sFlt-1 in causing preeclampsia-like features in an experimental model.51 It is possible that injection of preeclampsia serum in wild type or IL-10
/H11002
/H11002
mice triggers excess production of these anti-angiogenic factors. Thus, we assessed the effect of preeclampsia serum on the circulating levels of mouse sFlt-1 and sEng by using a mouse-specific ELISA. Injection of severe preeclampsia serum significantly elevated the levels of mouse sFlt-1 in IL-10
/H11002
/H11002
mice compared with NPS treatment without influencing wild type counterparts. Treatment with mPE serum did not induce the production of sFlt-1 in either wild-type or IL-10
/H11002
/H11002
mice. In IL-10
/H11002
/H11002
mice, mild preeclampsia serum treatment led to relatively significant increase in sEng but not sFlt-1 (Figure 2C). In addition, this treatment did not cause sFlt-1 or sEng production in wild type animals. In this context, sEng has been shown to induce

Figure 2. Preeclampsia serum induces glomerular endotheliosis and elevated sFlt-1 and sEng production. A: Histopathological analyses of renal tissue from representative NPS- or sPE-treated pregnant IL-10
/H11002
/H11002
(upper panel) and wild-type mice (lower panel) are shown (original magnification, ×100). H&E stain shows capillary occlusion in the sPE-treated IL-10
/H11002
/H11002
and wild-type animals with enlarged glomeruli and swollen endothelial cells compared with NPS-treated control mice. PAS-based staining of the sPE-treated mice shows inflammation of capillary endothelial cells (endotheliosis) in both IL-10
/H11002
/H11002
and wild-type animals. These pathological changes are absent in the NPS-treated mice. Similar results were observed with multiple serum samples. A representative image from the staining of at least three animals per group is shown. B: Circulating gd 17 mouse serum levels of sFlt-1 in response to a single-dose treatment with NPS (blue bar), sPE (magenta bar), and mPE (gray bar) are shown. Treatment with sPE induces excess production of sFlt-1 in IL-10
/H11002
/H11002
mice compared with NPS treatment without influencing wild type counterparts. Treatment with mPE serum did not induce the production of sFlt-1 in either wild-type or IL-10
/H11002
/H11002
mice. C: Circulating gd 17 mouse serum levels of sEng in response to treatment with NPS, sPE, or mPE are shown in the graph. Treatment with sPE induces excess production of sEng both in IL-10
/H11002
/H11002
mice as well as wild-type animals when compared with NPS treatment. Treatment with mPE induced moderate increase in the levels of sEng only in IL-10
/H11002
/H11002
mice. All values are expressed as the mean ± SD obtained from at least seven animals per treatment group. *P < 0.01 or **P < 0.05 represent significance over control NPS-treated groups.
hypertension and proteinuria. However, fetal growth restriction in pregnant rats was observed only when sFlt-1 was co-administered with sEng.51 These observations suggest that combined elevation of both sFlt-1 and sEng in IL-10 deficient mice is likely to contribute to severe pathology affecting all maternal symptoms as observed in Figures 1 and 2.

Nonpregnant Mice Are Resistant to Preeclampsia Serum-Associated Effects

To confirm the pregnancy-specific nature of our observations, we injected normal or severe preeclampsia serum samples in nonpregnant wild type or IL-10−/− female mice. The animals were monitored for blood pressure, proteinuria, and circulating levels of anti-angiogenic factors on the seventh day after treatment. Treatment with serum did not cause elevated blood pressure (Figure 3A), proteinuria (Figure 3B), or alter the levels of sFlt-1 in either IL-10−/− or wild type animals (Figure 3C). Moreover, the nonpregnant animals treated with severe preeclampsia serum did not experience renal pathology (data not shown), suggesting that the abnormalities observed in pregnant mice are linked pathophysiologically to the placenta.

In Vivo Treatment with Preeclampsia Serum Perturbs Spiral Artery Transformation

Spiral artery transformation is an essential feature of normal pregnancy that ensures the enhanced flow of nutrients and blood to the fetus. Poor remodeling of spiral arteries is a common histopathological feature of placental pathology affecting all maternal symptoms as observed in Figures 1 and 2. Perturbations in spiral artery remodeling, causing hypoxic/ischemic injury to the placenta and resulting in excess production of soluble factors that contribute to the maternal syndrome.10,11 Since our findings indicate impaired spiral artery remodeling and excess production of sFlt-1, we hypothesized that treatment with severe preeclampsia serum could cause hypoxic injury in IL-10−/− mice. We used a widely used method of hypoxia detection by EF5 (2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide).45,46,50 As described in Materials and Methods, this compound is injected i.p. 4 hours before sacrificing the animal. Uteroplacental tissue was collected and stained with an antibody against EF5. A representative section of uteroplacental tissue from IL-10−/− mice sacrificed on gd 14 and stained is shown in Figure 4B. Cells expressing EF5 are stained red, and nuclei are stained blue. The average area of spiral arteries in wild type and IL-10−/− mice was quantified and is shown in Figure 4B. Treatment with normal pregnancy serum but not normal pregnancy serum significantly reduced the circumference of modified spiral arteries and the total number of transformed spiral arteries in the mesometrial region in IL-10−/− mice. There was a statistically insignificant effect of different treatments in the wild type animals as shown in Figure 4B. Morphometric analysis of the spiral arteries at higher magnification (×40) using One Spot software (Figure 4A, lower panel) clearly showed that treatment of IL-10−/− mice with severe preeclampsia serum significantly blocked the transformation of spiral arteries.

Figure 3. Severe preeclampsia serum does not induce disease-like symptoms in nonpregnant mice. Nonpregnant wild-type or IL-10−/− female mice were injected with NPS or sPE samples. Seven days after a single administration as described for pregnant mice, blood pressure was monitored, and urine and serum samples were analyzed. A: No changes were observed in the readings of systolic blood pressure in nonpregnant mice irrespective of treatment with NPS (blue bar) or sPE (magenta bar). B: Proteinuria values from urine samples collected over a 24-hour period in response to different treatments are shown. Treatment with sPE did not induce significant proteinuria in either wild-type or IL-10−/− mice compared with NPS treatment. C: Circulating mouse serum levels of soluble Flt-1 (sFlt-1) in response to a single-dose treatment of NPS or sPE are shown. No significant differences were observed between NPS (blue bar) and sPE (magenta bar). All of the values were obtained from at least five animals per treatment group and are expressed as the mean ± SD. The numbers in parentheses indicate the number of different serum samples tested in the study.
treatment as suggested by intense immuno-fluorescent staining for EF5. Since the response to hypoxia is regulated by hypoxia-inducible factors, we evaluated HIF 1α protein levels by Western blotting in IL-10−/−/− uteroplacental tissue collected on gd 12. As shown in Figure 5B, treatment with preeclampsia serum significantly induced the protein levels of HIF 1α. These results suggest that preeclampsia serum induces significant hypoxia at the maternal-fetal interface in IL-10−/−/− mice.

**Preeclampsia Serum Disrupts Endovascular Activity in Vitro**

Since preeclampsia serum impaired spiral artery remodeling and induced production of anti-angiogenic factors, we hypothesized that these serum samples would disrupt the endovascular interaction between endothelial cells and trophoblasts. We used an in vitro model that we recently established34,41,48 to assess serum samples from women with preeclampsia that were collected at 32 to 36 weeks and compared them with gestational age-matched serum from normal pregnancies for their effect on endovascular interaction between endothelial cells and trophoblasts on matrigel. Normal pregnancy serum supported the endothelial cell-guided tube formation by first trimester trophoblast HTR8 cells (Figure 6A). In contrast, serum from severe or mild preeclampsia disrupted the endovascular cross talk between endothelial cells and trophoblasts (Figure 6B). Interestingly, the endovascular disrupting activity was independent of the serum levels of human sFlt-1 and sEng. Normal pregnancy serum spiked with amounts of recombinant sFlt-1 or sEng equal to that found in preeclampsia serum samples did not perturb tube formation (see Supplemental Figure S4 at http://ajp.amjpathol.org). However, it should be pointed out that endogenous sFlt-1 or sEng could differ from their recombinant counterparts in functional potency. We also ruled out the disruption of endovascular interaction by apoptotic cell death induced by serum.56 We analyzed the cytotoxic potential of serum samples on endothelial cells and first trimester HTR8 trophoblast cells by FACS analysis. As shown in Figure 6C, preeclampsia serum did not induce significant cell death as compared with normal pregnancy serum in either of the cell types.

**Gestational Age-Dependent Longitudinal Studies Confirm the Presence of Tube-Disrupting Activity at 12 to 14 Weeks**

Preeclampsia is typically diagnosed late in pregnancy. We propose that the molecular events leading to clinical manifestation of preeclampsia are likely to begin at earlier stages of pregnancy. Thus, we evaluated the sensitivity of our in vitro model to predict the gestational age-dependent effects of preeclampsia serum. We used serum samples drawn from patients at 12 to 14, 22 to 27, and 32 to 36 weeks of pregnancy who either experienced normal pregnancy or were given a diagnosis of preeclampsia after week 24. As shown in Figure 6D, normal pregnancy serum samples from different gestational ages support robust tube formation. In contrast, serum samples from preeclamptic women increasingly showed tube-disrupting activity that correlated with gestational age. Importantly, endovascular disruptive activity could be observed as early as 12 to 14 weeks’ gestation. These results suggest that our in vitro three-dimensional tube formation assay can be successfully used to predict the onset of preeclampsia.
that favors the prevalence of an anti-angiogenic phenotype are often associated with a maternal profile. Course and programming of this heterogeneous condition induces the full spectrum of symptoms mirroring the human condition. Wild type and IL-10−/− mice differed in their response to serum as the former only experienced preeclampsia-like symptoms without IUGR possibly related to lack of increase in serum sFlt-1 levels. This suggests that gene-environment interactions are able to impart graded pathology in response to causative factors. The differential activity of serum samples from mild or severe preeclampsia could not be attributed to the varying concentrations of sFlt-1 and sEng because several preeclampsia serum samples showed values of these factors as the samples from normal pregnancy (see Supplemental Figure S3 at http://ajp.amjpathol.org). The fact that only serum from the severe patients, but not mild preeclampsia or normal pregnancy, caused renal pathology in both wild type and IL-10−/− mice again suggests that intrinsic gene-environment interactions are able to impart graded pathology in response to causative factors. The differential activity of serum samples from mild or severe preeclampsia could not be attributed to the varying concentrations of sFlt-1 and sEng because several preeclampsia serum samples showed values of these factors as the samples from normal pregnancy (see Supplemental Figure S3 at http://ajp.amjpathol.org).

Several studies have shown that hypoxia could be an upstream factor that promotes placental pathology including apoptosis, increase in oxidative stress, shedding of villous microparticles, and elevated production of angiogenic factors such as sFlt-1 and sEng. Hypoxia-induced HIF 1α accumulation in the placenta is associated with defective trophoblast invasion into spiral arteries possibly resulting in remodeling defects and further ischemia. Moreover, HIF 1α has been shown to be expressed in the placenta from preeclamptic subjects. Hypoxia has also been shown to affect cytokine balance by reducing IL-10 production and promoting IL-6 and IL-8 in placental explants and trophoblasts. As evident from our studies, preeclampsia serum was indeed associated with placental hypoxia as indicated by EF5 incorporation in the decidua basalis and the junctional zone with significant induction of HIF 1α in IL-10−/− mice. We did not observe a similar effect in the wild type counterparts. Both F1t-1 and Eng genes contain hypoxia-inducible factor-1 binding sites and are known to be under hypoxic regulation. Specifically, hypoxia has been shown to trigger HIF 1α expression with excess production of sFlt-1 and sEng in trophoblasts from preeclamptic placentas. Thus, placental hypoxic injury with preeclampsia serum could be a possible cause for production of sFlt-1 and sEng in IL-10−/− mice.

As a consequence of the placental hypoxic injury, our observations on impaired spiral artery remodeling in IL-10−/− mice in response to preeclampsia serum are noteworthy. In the human condition, impaired spiral artery
remodeling is a clinical histological feature possibly due to inefficient trophoblast invasion.\(^{52,54}\) Although the trophoblast invasion in mice is relatively shallow as compared with humans, multiple studies with mice have shown that spiral artery remodeling occurring during normal pregnancy could be perturbed by uterine natural killer cell dysregulation and by inhibition of the water channel, aquaporin 1, at the maternal-fetal interface.\(^{34,37}\)

It is thus possible that in preeclampsia serum-treated mice, dysregulated cross talk between uterine natural killer cells and endothelial cells as a result of hypoxic injury or altered angiogenesis-cytokine machinery, not trophoblast invasion, may be a major regulator of spiral artery remodeling. In the context of human pregnancy, we have been able to demonstrate an in vitro model of impaired cross talk between trophoblasts and endothelial cells by preeclampsia serum. In this model, extravillous trophoblasts from first trimester uniquely fingerprint the endothelial cell-guided tube formation under pregnancy milieu provided by normal pregnancy serum.\(^{41}\)

Under identical conditions, preeclampsia serum from both mild and severe conditions consistently disrupted this endovascular cross talk. The disruption of tube formation by preeclampsia serum was graded according to the severity of the disease and was, at least partly, independent of the serum levels of sFlt-1, sEng, vascular endothelial growth factor, or PIGF (data not shown). Importantly, using this bioassay with samples from a longitudinal study, we demonstrated disruption of endovascular trophoblast interaction by serum samples from patients with preeclampsia collected as early as 12 to 14 weeks of pregnancy. This observation is significant in view of the fact that the disease is clinically manifest as symptoms that typically occur only in the third trimester of pregnancy. Moreover, the heterogeneous nature of the disease has hampered the search for discovery of “biomarkers” applicable to the majority of patient population. In this regard, our in vitro predictive assay using serum from pregnant women is likely to provide a robust approach to study disease-related changes and to blueprint placental pathology. Longitudinal studies and a larger collection of patient serum samples that validate the bioassay may have the potential to identify a functional biomarker. In this regard, we are currently evaluating serum samples from 12 to 14 weeks’ gestation for their ability to cause preeclampsia-like symptoms in IL-10\(^{-/-}\) mice. Identification of causative factor(s) present in preeclampsia serum responsible for the in vivo and in vitro observations presented here is currently under investigation.

Collectively, our data support the “blueprint” concept of preeclampsia serum as demonstrated here in a novel semihumanized mouse model of preeclampsia and in an in vitro bioassay for predicting the onset of preeclampsia. Since a multifactorial etiology has been widely discussed for preeclampsia, we propose that the pregnancy-specific IL-10\(^{-/-}\) mouse model that closely mirrors the hu-
man condition is suitable for now studying the complex myriad of molecular events and for testing novel therapeu-
tic interventions. This model could be further im-
proved by using the telemetry approach in place of the
tail cuff blood pressure measuring device and by better
characterizing the renal histology using electron micro-
scopy. Our results also suggest that a possible role of
IL-10 should be investigated in preeclampsia in humans.

Acknowledgments

We are grateful to all of the mothers participating in this
study. We thank Udo Markert, Brenna Anderson, and
Jared Robbins for a critical reading of the article.

References

2. Redman CW, Sargent IL: Latest advances in understanding pre-
3. Ilekis JV, Reddy UM, Roberts JM: Preeclampsia—a pressing
problem: an executive summary of a National Institute of Child
4. Moris M, Perico N, Remuzzi G: Mechanisms of disease: pre-eclamp-
5. Redman CWG, Sargent IL: Placental debris, oxidative stress and
6. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schister-
man EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP,
Karumanchi SA: Circulating angiogenic factors and the risk of the
7. Roberts JM, Cooper DW: Pathogenesis and genetics of pre-eclamp-
8. Hiby SE, Walker JJ, O'Shaughnessy KM, Redman CW, Carrington M,
Mallows J, Moffett A: Combinations of maternal KIR and fetal HLA-A genes
influence the risk of preeclampsia and reproductive success.
Sharma S: Evidence of non-cytotoxic uterine natural killer cells. Am J
11. Roberts JM, Hubel CA: The two stage model of preeclampsia: vari-
Altito K, Darmsky C, Fisher SJ: Vascular endothelial growth factor
ligands and receptors that regulate human cytotrophoblast survival are
dysregulated in severe preeclampsia and hemosysis, elevated
layer enzymes, and low platelets syndrome. Am J Pathol 2002,
160:1405–1423.
13. Levine RJ, Larm C, Qian C, YuKF, Maynard SE, Sachs BP, Sibai BM,
Epstein FH, Romero R, Thadhani R, Karumanchi SA, CEPF Study
Group: Soluble endoglin and other circulating anti-angiogenic factors
JP, Gotsch F, Erezz O, Mazaki-Tobi S, Gomez R, Edwin S, Chaiworap-
ongs A, Levine RJ, Karumanchi SA: A longitudinal study of angiogenic
(placental growth factor) and anti-angiogenic (soluble endoglin and
soluble endothelial growth factor receptor-1) factors in normal
pregnancy and patients destined to develop preeclampsia and deliver a
small for gestational age neonate. J Matern Fetal Neonatal Med 2008,
21:9–23.
A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H,
Luft FC: Patients with preeclampsia develop agonistic autoantibodies
against the angiotensin AT1 receptor. J Clin Invest 1999,103:945–952.
17. Herse F, Staff AC, Hering L, Müller DN, Luft FC, Dechend R: AT1-
receptor autoantibodies and uteroplasental angiotensin II (Ang II) in
18. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Posek EJ, Hicks MJ,
Ramin SM, Kellems RE, Xia Y: Angiotensin receptor agonistic auto-
antibodies induce preeclampsia in pregnant mice. Nat Med 2008,
14:855–862.
Parry S, Augustin HG, Gattone VH, Folkman J, Strauss JF, Kalluri R:
Deficiency in ctechole-0-methytranferase and 2-mercaptoethanol
Okihosi E, Ohi H, Kyohosu F, Tochgi M, Satoh K, Shimizu T,
Nishinariya S, Nemoto N, Sakurai I: Murine fetal resorption and expor-
timental pre-eclampsia are induced by both excessive TH1 and TH2
23. Takimoto E, Ishida J, Sugiyama H, Horiguchi H, Murakami K, Fuka-
mizu A: Hypertension induced in pregnant mice by placental renin
24. Kobayashi N, Takakashi K, Matsuura T, Sugimura M, Kobayashi T,
Moniwa N, Tomita M, Nakayama K: Deficiency in p57kip2 expression
induces preeclampsia-like symptoms in mice. Mol Hum Reprod 2002,
8:1129–1135.
DC, Sethi S, Weiss RM, Bates JW: Discovery of a spontaneous ge-
27. Falcao S, Solomon C, Monat C, Bérejé J, Gutkowska J, Lavoie JL:
Impact of diet and stress on the development of preeclampsia-like
symptoms in p57kip2 mice. Am J Physiol Heart Circ Physiol 2009,
28. Hanna N, Hanna I, Hieb M, Wagner E, Dougherty J, Baikundi D,
Padbury J, Sharma S: Gestational age-dependent expression of IL-10
and its receptor in human placental tissues and isolated cytoto-
Sharma S: Evidence for interleukin-10-mediated inhibition of cyclo-
oxigenase-2 expression and prostaglandin production in preterm
30. Plevyak M, Hanna N, Mayer S, Murphy S, Pinar H, Fast L, Ekerelt C,
Emerudh J, Berg G, Matlithsen L, Sharma S: Deficiency of decidual
accelerated IL-10 in first trimester missed abortion: a lack of correlation with the
decidual immune cell profile. Am J Reprod Immunol 2002,47:
242–250.
31. Robertson SA, Skinner RJ, Care AS: Essential role for IL-10 in resis-
tance to lipopolysaccharide-induced preterm labor in mice. J Immunol
2006,177:4888–4896.
32. Murphy SP, Hanna NN, Fast LD, Shaw SK, Berg G, Padbury JF,
Romero R, Sharma S: Evidence for participation of uterine natural
killer cells in the mechanisms responsible for spontaneous preterm
33. Thaxton JE, Romero R, Sharma S: TLR9 activation coupled to IL-10
deficiency induces adverse pregnancy outcomes. J Immunol 2009,
183:1144–1154.
34. Tewari N, Kalkunte S, Murray DW, Sharma S: The water channel
aquaporin 1 is a novel molecular target of polychlorinated biphenyls
35. Hennessy A, Pilmore HL, Simmons LA, Painter DM: A deficiency of
Hanna J, Goldberg W-D, Hamani Y, Avraham I, Greenfield C.